间断口服伐昔洛韦预防多发性骨髓瘤患者应用硼替佐米致带状疱疹的.PDF

中国癌症杂志 2014年第24卷第7期 《 》 CHINA ONCOLOGY 2014 Vol.24 No.7 525 间断口服伐昔洛韦预防多发性骨髓瘤 患者应用硼替佐米致带状疱疹 的临床观察 姚一芸　唐勇　庄衍　汪蕾　邹丽芳　朱琦 上海交通大学医学院附属第九人民医院血液内科，上海 200011 　　［摘要］　背景与目的： 随着硼替佐米成功用于多发性骨髓瘤的治疗，药物导致带状疱疹激活现象受到关 注。本研究探讨硼替佐米治疗期间伐昔洛韦不同用药方法预防带状疱疹的效果。方法：31例多发性骨髓瘤患者 随机分成伐昔洛韦间断应用组和连续应用组，分别观察2组患者带状疱疹发生情况、药物不良反应、抗病毒治 疗费用及情绪状态。结果：2组患者治疗期间均未合并带状疱疹，未发生3级以上药物不良反应，间断用药组的 抗病毒费用支出低于连续治疗组。患者情绪取决于基础疾病疗效，既往治疗不理想的连续用药组患者有焦虑抑 郁表现。结论：伐昔洛韦间断应用能够有效预防硼替佐米治疗期间多发性骨髓瘤患者带状疱疹发生。 　　［关键词］　多发性骨髓瘤；硼替佐米；带状疱疹；伐昔洛韦 　　DOI: 10.3969/j.issn.1007-3969.2014.07.009 　　中图分类号：R738.1　　文献标志码：A　　文章编号：1007-3639(2014)07-0525-04 Intermittent administration of valacyclovir is effective for prevention of herpes zoster events in patients with multiple myeloma treated with bortezomib YAO Yi-yun, TANG Yong, ZHUANG Yan, WANG Lei, ZOU Li-fang, ZHU Qi (Department of Hematology, Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China) Correspondence to: ZHU Qi E-mail: zhuqi70@ 　　［Abstract ］ Background and purpose: Herpes zoster is a common adverse event associated with the use of bortezomib. The objective of this study was to evaluate the efficacy of different therapeutic regimens of valacyclovir prophylaxis: continuously administration and intermittent administration. Methods: We retrospectively analyzed the efficacy, side effects, expense of valacyclovir and emotional states of 31 patients with multiple myeloma who received bortezomib and valacyclovir prophylaxis. Among them, 14 patients underwent continuously administration of valacyclovir, the other 17 patients underwent intermittent administration. Continuously administration was defined